{
    "nctId": "NCT03541863",
    "briefTitle": "Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients",
    "officialTitle": "What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 131,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who were treated with Fulvestrant between June 2014 to June 2017 as first line or second line therapy\n* Patients received subsequent treatment after progressing on Fulvestrant for at least one cycle (\\>1 month)\n* Complete medical history was available\n\nExclusion Criteria:\n\n* Subsequent treatment was not standard therapy (cannot be classified into endocrine therapy/ chemotherapy)\n* Medical history was incomplete",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}